The Role of Pregabalin in Fibromyalgia
|
|
- Eugenia Green
- 6 years ago
- Views:
Transcription
1 The Role of Pregabalin in Fibromyalgia Sofia Exarchou Resident at Internal Medicine and Rheumatology at the University Hospital of Skåne, Malmö-Lund Metsovo Greece 2011
2 History Gowers 1904 Hench 1976 Smythe & Moldofsky 1979 American College of Rheumatology 1990
3 ACR criteria 1990 Classification criteria Not diagnostic!!!!! Widespread pain in all four quadrants of the body for 3 months Tenderness on pressure in at least 11 of 18 scecified sites
4 Realities about ACR criteria 1990 The clinical diagnosis in primary care does not ordinarily involve a tender point count or an adequately executed tender point count when performed The case definition of FM has changed somewhat with increasing recognition of the importance of cognitive problems and somatic symptoms Diagnostic criteria ACR 2010 Wolf F. Et al. Atrhritis Care & Research. May ;5:
5
6
7
8 Mechanism of action of Pregabalin Excessive neurotransmitter release in hyperexcited neuron Pregabalin reduces excessive neurotransmitter release
9 Indications of Pregabalin Neuropathic pain from diabetic neuropathy or post-herpetic neuralgia Adjunctive therapy in adults with partial seizures with or without secondary generalization. Generalized anxiety disorder (EU) Fibromyalgia (FDA 21 June 2007)
10
11 RCTs Trial 105 Pregabalin for the treatment of fibromyalgia syndrome: results of a RCT. Crofford LJ et al. Arthritis Rheum 2005;52: Trial 1056 A RCT phase III of pregabalin in the treatment of patients with fibromyalgia. Mease PJ et al. J Rheumatol 2008;35: Trial 1077 A 14-week, RCT monotherapy of pregabalin in patients with fibromyalgia. Arnold LM et al. J Pain 2008;9: Trial 1100 Pregabalin for the management of fibromyalgia: a 14-week RCT Pauer L et al. Ann Rheum Dis 2008;67(suppl 2):256 Trial 1059 FREEDOM Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief: a 6-month RCT Crofford LJ et al. Pain 2008;136:419-31
12 Trial characteristics
13 Inclusion Exclusion criteria Patients 18 yrs Women - neither pregnant nor lactating - postmenopausal, surgically sterilized, using contraception. ACR criteria for FM. VAS-pain scores 40/100mm after stopping any relevant pain or sleep medication. Important exclusion criteria: - severe pain due to other conditions - rheumatic diseases other than FM - active infections - untreated endocrine disorders - severe depression - active malignancy - immunocompromised - other severe acute or chronic medical or psycgiatric conditions or laboratory abnormalities.
14 Trial characteristics
15 Outcomes chosen for meta-analysis of the four classical design RCTs Mean weekly pain scores 30% - 50% responders ( pat achieving at least 30% or 50% pain relief) PGIC Patient Global Impression of Change ( much or very much improvement) FIQ Fibromyalgia Impact Questionnaire MOS-sleep: mean sleep quality score SF-36: HRQOL MAF global index: Multidimentional Assessment of Fatigue global index HADS Hospital Anxiety and Depression Scale Additional analgesic consumption Adverse events Discontinuations Weight gain
16 Trial characteristics
17 Trial characteristics
18 Pooled weekly mean pain scores for the 4 classical RCTs
19 Efficacy Outcomes Pooled Analysis of the 4 classical design RCTs
20 Efficacy Outcomes Pooled Analysis of the 4 classical design RCTs
21 Efficacy Outcomes Pooled Analysis of the 4 classical design RCTs
22 Efficacy Outcomes Pooled Analysis of the 4 classical design RCTs
23 Efficacy Outcomes Pooled Analysis of the 4 classical design RCTs
24 Efficacy Outcomes Pooled Analysis of the 4 classical design RCTs
25 Efficacy Outcomes Pooled Analysis of the 4 classical design RCTs
26 FREEDOM Study Open label phase 50% του VAS-πόνου PGIC: much or very much Double-blind phase 54%
27 FREEDOM Study
28 FREEDOM Study
29
30 FREEDOM Study Open label phase: - 82% experienced at least one adverse event - most common: dissiness and somnolence - 19% withdrew because of AEs - 0,8% serious ΑΕs Double-blind phase: - 45% placebo - 59% taking 300mg - 63% taking 450mg - 62% taking 600mg Experienced an AE
31 Conclusions - efficacy PGB significantly improved pain and other symptoms of FM. A dose-response relationship could only be shown for 50% responders, a measurement constituting substantial improvement. At least 50% pain relief was obtained by only 24% of the people taking PGB at the higher doses mg/d. While applicable only to a minority, this is an important outcome to those people who achieve it. A 6-week trial of PGB was sufficient to identify responders, enabling an early decision about lack of response and choice of alternative therapy Sustained benefit over 26 weeks, with loss of therapeutic response occurring soon after randomization, and being uncommon after 14 weeks.
32 Effect of trial design on efficacy estimates
33 Conclusions - AEs Most people in PGB and placebo groups experienced AEs This is not surprising considering the range of symptoms associated with FM, some of which may be reported as AEs in a clinical trial The rate of serious AEs was roughly similar, and low with PGB and placebo Some AEs such as weight gain, somnolence and dizziness are typical of PGB and occurred most commonly with PGB. For dizziness, clear dose dependence was apparent over the range mg/d
34 How to interpret these data in terms of the individual patient? To make trial data more relevant would require individual patient analysis showing that patients who benefited on one outcome, like pain, showed relevant clinical improvements in all or many of the major outcomes.
35 Non-pharmacologic therapy Heated pool treatment with or without exercise Individually tailored exercise programmes, including aerobic exercise and strength training Cognitive behavioural therapy Relaxation, rehabilitation, physiotherapy and psychological support Pharmacotherapy Tramadol Simple analgesics such as paracetamol and other weak opioids Antidepressants: amitriptyline, fluoxetine, duloxetine, milnacipran, moclobemide and pirlindole Tropisetron, pramipexole and pregabalin
36 Comparison of PGB with other treatments for FM There is no clear evidence of superiority of one drug over another in FM at present, because thhe drug we have produce a substantial benefit in only a minority of patients We do not know whether patients who respond to one would also respond to another. On average a number of drugs seen to be roughly equally effective, but individual patients may respond to one drug better than another. Various treatment options should be made available to patients.
37 Clinical challenge in FM lies in finding the right combination of treatments, pharmacological and/or non-pharmacological, best suited to individual patients. This will in part be empirical, at least until sub/types of FM with distinct pathophysiology can be differentiated, and drug choice informed by mechanistic or genetic determinants. Both then and now, there will be a need for tailored treatment for individual patients
National Horizon Scanning Centre. Pregabalin (Lyrica) for fibromyalgia. September 2007
Pregabalin (Lyrica) for fibromyalgia September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationAssistant Professor. Dr.Khudair Al-bedri Consultant Rheumatology & Internal Medicine.
Assistant Professor Dr.Khudair Al-bedri Consultant Rheumatology & Internal Medicine. Fibromyalgia Fibromyalgia is a syndrome of chronic pain and the presence of hyperalgesic points at specific anatomical
More informationFibromyalgia (FM) is a common, chronic pain disorder
ORIGINAL ARTICLE Long-term Maintenance of Response Across Multiple Fibromyalgia Symptom Domains in a Randomized Withdrawal Study of Pregabalin Lynne Pauer, MS,* Gary Atkinson, MSc,w T. Kevin Murphy, PhD,z
More information10/26/2013. Mary-Ann Fitzcharles is a consultant, speaker, or member of an advisory board for the following companies: Lilly, Purdue, Pfizer, Valeant
Mary-Ann Fitzcharles, MBChB Associate Professor of Medicine Division of Rheumatology and Alan and Louise Edwards Pain Management Center McGill University, Montreal Canada Mary-Ann Fitzcharles is a consultant,
More informationHeadaches, 37, 42 Hypnotherapy, 101t, 106 Hypothalamic-pituitary-adrenal (HPA) axis, 59, 61, 63, 64, 65
INDEX Note: page numbers in italic typeface indicate figures. Page numbers followed by a t indicate tables. Abbreviations are for terms listed on pages 135-137. Acetaminophen/tramadol in fibromyalgia,
More informationComparative Efficacy of Pharmacological and Nonpharmacological Interventions in Managing Primary and Secondary Outcomes of Fibromyalgia Syndrome
Literature Review Comparative Efficacy of Pharmacological and Nonpharmacological Interventions in Managing Primary and Secondary Outcomes of Fibromyalgia Syndrome * Medical University of the Americas,
More informationFibromyalgia: What Primary Care Providers Need to Know
Learning Objectives Fibromyalgia: What Primary Care Providers Need to Know Susan Hutchinson, MD Director, Orange County Migraine & Headache Center Volunteer Clinical Faculty, UC Irvine Department of Family
More informationRecommendations for the Management of Fibromyalgia
2011 UBM Medica. Reprinted with permission from Medical Progress 2011 Vol. 38 No. 1. Pain management Recommendations for the Management of Fibromyalgia The Multidisciplinary Panel on Neuropathic Pain Chen
More informationOn March 21, 2009, The American Journal of Managed Care
n report n Contemporary Management Strategies for Fibromyalgia On March 21, 2009, The American Journal of Managed Care (AJMC) held a roundtable of clinical, patient advocacy, and managed care experts to
More informationIf Not Opioids then LEAH EDMONDS CSHP OCTOBER 26, 2017
If Not Opioids then what LEAH EDMONDS CSHP OCTOBER 26, 2017 Disclosure Nothing to disclose Objectives Identify various non-opioid options for the treatment of chronic non cancer pain Choose appropriate
More informationExecutive Summary Pregabalin (Lyrica by Pfizer) Formulary Review
Executive Summary Pregabalin (Lyrica by Pfizer) Formulary Review Lyrica (pregabalin) is a new prescription medication indicated for use in painful diabetic peripheral neuropathy (DPN), post-herpetic neuralgia,
More informationFibromyalgia Update. Presenter: Manfred Harth MD FRCPC
Fibromyalgia Update Presenter: Manfred Harth MD FRCPC Fibromyalgia Update Manfred Harth MD FRCPC Disclosures Member Pfizer Canada Medical Advisory Committee on Lyrica (till April 2013) Abbvie : Payment
More information5.9. Rehabilitation to Improve Central Pain
5.9. Rehabilitation to Improve Central Pain Evidence Tables and References Canadian Best Practice Recommendations for Stroke Care 2011-2013 Update Last Updated: June 25 th, 2013 Contents Search Strategy...
More informationDOWNLOAD OR READ : TREATING FIBROMYALGIA PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : TREATING FIBROMYALGIA PDF EBOOK EPUB MOBI Page 1 Page 2 treating fibromyalgia treating fibromyalgia pdf treating fibromyalgia Narcotic medications (opioids) are controversial in the
More informationEvolving Treatments for Patients with Fibromyalgia
4:30pm - 5:30pm: Breakout 5 - Women s Health Option C: Evolving Treatments for Patients with Fibromyalgia ACPE UAN 0107-0000-10-027-L01-P 0.1 CEU/1.0 Hr. Activity Type: Application-Based Program Objectives
More informationFibromyalgia in Family Medicine: Challenges in Pain Management
Fibromyalgia in Family Medicine: Challenges in Pain Management Evidence-based Recommendations The practice recommendations in this presentation are from: The European League Against Rheumatism (EULAR)
More informationContent and Criterion Validity of the Preliminary Core Dataset for Clinical Trials in Fibromyalgia Syndrome
Content and Criterion Validity of the Preliminary Core Dataset for Clinical Trials in Fibromyalgia Syndrome ERNEST H. CHOY, LESLEY M. ARNOLD, DANIEL J. CLAUW, LESLIE J. CROFFORD, JENNIFER M. GLASS, LEE
More informationCOMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING FOR PAIN MANAGEMENT
JANUARY 2012 COMPOUNDING PHARMACY SOLUTIONS PRESCRIPTION COMPOUNDING WWW.CPSRXS. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Osteoarthritis Pain
More informationFran Pulver, MD - PM&R Laurie Bell, PT - Physical Therapy Gregg Weidner, MD - Anesthesia Steven Severyn, MD, MBA, MSS - Anesthesia
Fran Pulver, MD - PM&R Laurie Bell, PT - Physical Therapy Gregg Weidner, MD - Anesthesia Steven Severyn, MD, MBA, MSS - Anesthesia Case Presentation-Fibromyalgia 30 year old female Chief complaint of back
More informationIs Sodium Oxybate a Safe and Effective Treatment for Patients with Fibromyalgia
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2012 Is Sodium Oxybate a Safe and Effective
More informationFibromyalgia: Current Trends and Concepts
Fibromyalgia: Current Trends and Concepts Dr. Brian Kahan Fellow American Academy of Physical Medicine and Rehabilitation Diplomat American Academy of Pain Medicine American College of Rheumatology (ACR)
More informationNurse Practitioners Education, Awareness, and Therapeutic Approaches for the Management of Fibromyalgia
RESEARCH 2.0 ANCC Contact Hours Nurse Practitioners Education, Awareness, and Therapeutic Approaches for the Management of Fibromyalgia Linda Hughes Jean Adair Feng Feng Stephanie Maciejewski Harsha Sharma
More informationDon L. Goldenberg, MD,* Daniel J. Clauw, MD, Robert H. Palmer, MD, Philip Mease, MD, Wei Chen, PhD, and R. Michael Gendreau, MD, PhD**
Pain Medicine 2010; 11: 180 194 American Academy of Pain Medicine Durability of Therapeutic Response to Treatment for Fibromyalgia. Results of a Randomized, Double-Blind, Monotherapy 6-Month Extension
More informationThe Effect of Anxiety and Depression on Improvements in Pain in a Randomized, Controlled Trial of Pregabalin for Treatment of Fibromyalgia
Blackwell Publishing IncMalden, USAPMEPain Medicine1526-2375American Academy of Pain Medicine? 200788633638 RESEARCH ARTICLEAnxiety and Depression in Fibromyalgia PatientsArnold et al. PAIN MEDICINE Volume
More informationFIBROMYALGIA. Howard L. Feinberg, D.O. F.A.C.O.I., F.A.C.R. OPSC San Diego 2017
FIBROMYALGIA Howard L. Feinberg, D.O. F.A.C.O.I., F.A.C.R. OPSC San Diego 2017 Sir William Osler When a patient with arthritis comes in the front door, I try to go out the back door. FEINBERG S COROLLARY
More informationScottish Medicines Consortium
Scottish Medicines Consortium pregabalin, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg capsules (Lyrica ) No. (389/07) Pfizer Limited 6 July 2007 The Scottish Medicines Consortium has completed
More informationManagement of fibromyalgia: Current pharmacologic therapies & recommendations for therapeutic optimisation
Page 1 of 5 Management Management of fibromyalgia: Current pharmacologic therapies & recommendations for therapeutic optimisation M Slim, EP Calandre* Abstract Introduction Fibromyalgia is a chronic musculoskeletal
More informationLyrica. Lyrica, Lyrica CR (pregabalin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.18 Subject: Page: 1 of 7 Last Review Date: March 16, 2018 Description, CR (pregabalin) Background
More informationDrug Class Review Drugs for Fibromyalgia
Drug Class Review Drugs for Fibromyalgia Final Original Evidence Tables April 2011 The Agency for Healthcare Research and Quality has not yet seen or approved this report The purpose of reports is to make
More informationFIBROMYALGIA. Leena Mathew, M.D. Director Pain Fellowship Associate Professor Department of Anesthesiology Columbia University
FIBROMYALGIA Leena Mathew, M.D. Director Pain Fellowship Associate Professor Department of Anesthesiology Columbia University disclosures I have no conflicts of interest objectives Be able to accurately
More informationCHRONIC PAIN MANAGEMENT
CHRONIC PAIN MANAGEMENT Betty J Harris, PharmD. 2014 Objectives Explain the consequences of untreated pain. Identify common causes of chronic non-malignant pain in adults. Identify steps to assessing pain,
More informationThis continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC.
This continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC. Indiana University School of Medicine and CME Outfitters, LLC, gratefully acknowledge
More informationLyrica. Lyrica (pregabalin) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.18 Subject: Lyrica Page: 1 of 6 Last Review Date: June 22, 2017 Lyrica Description Lyrica (pregabalin)
More informationMaking sense of fibromyalgia syndrome. Charles Radis D.O. Clinical Professor of Medicine UNECOM
Making sense of fibromyalgia syndrome Charles Radis D.O. Clinical Professor of Medicine UNECOM Goals 1. How do we diagnose fibromyalgia syndrome in patients presenting with widespread pain? 2. Discuss
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More informationDevelopment of Responder Definitions for Fibromyalgia Clinical Trials
ARTHRITIS & RHEUMATISM Vol. 64, No. 3, March 2012, pp 885 894 DOI 10.1002/art.33360 2012, American College of Rheumatology Development of Responder Definitions for Fibromyalgia Clinical Trials Lesley M.
More informationFibromyalgia. What is fibromyalgia? What causes fibromyalgia? Who gets fibromyalgia? What are the symptoms of fibromyalgia?
Page 1 of 5 Fibromyalgia Fibromyalgia typically causes persistent pains and tenderness in many areas of the body as well as tiredness. You may also have other symptoms. There is no simple 'once and for
More informationPathway for management of chronic widespread pain Diagnosis of fibromyalgia 8
Pathway for management of chronic widespread pain Diagnosis of fibromyalgia 8 A patient satisfies diagnostic criteria for fibromyalgia if the following 3 conditions are met: 1. Widespread pain index (WPI)
More informationFibromyalgia or Arthritis
Fibromyalgia or Arthritis All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or mechanical, including photocopying,
More informationFibromyalgia. November 3, 2018 Raymond Hong, MD, MBA
Fibromyalgia November 3, 2018 Raymond Hong, MD, MBA The following report is proprietary information and constitutes trade secrets of The MetroHealth System and may not be disclosed in whole or part to
More informationOh My Aching Body Understanding Fibromyalgia
Page 1 Oh, My Aching Body: Understanding Fibromyalgia Geneva Clark Briggs, PharmD, BCPS This program has been brought to you by PharmCon Oh, My Aching Body: Understanding Fibromyalgia Accreditation: Pharmacists:
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Lyrica / Pregabalin
More informationTreatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am
Treatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am Tim R Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy Cleveland Clinic Akron General Center for Family
More informationTreatments for Fibromyalgia in Adult Subgroups
Draft Comparative Effectiveness Review Number XX Treatments for Fibromyalgia in Adult Subgroups Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540
More informationAdvice following an Independent Review Panel (IRP)
Scottish Medicines Consortium Advice following an Independent Review Panel (IRP) Pregabalin 25, 50, 75, 100, 150, 200 and 300mg capsules (Lyrica ) Pfizer No. 157/05 7 July 2006 The Scottish Medicines Consortium
More informationPharmacological and Nonpharmacological Approaches
Pharmacological and Nonpharmacological Approaches NAS Workshop December 4, 2018 Kurt Kroenke, MD, MACP Indiana University School of Medicine Regenstrief Institute, Inc. Balanced Treatment Options Medications
More informationTreating Pain Based on the Underlying Mechanisms: Maybe sometimes it is all in their head...
Treating Pain Based on the Underlying Mechanisms: Maybe sometimes it is all in their head... Daniel J. Clauw M.D. dclauw@umich.edu Professor of Anesthesiology, Medicine (Rheumatology), and Psychiatry Director,
More informationThe Impact of Centralized Pain on Acute and Chronic Post-surgical Pain
The Impact of Centralized Pain on Acute and Chronic Post-surgical Pain Chad M. Brummett, M.D. Associate Professor Director, Clinical Anesthesia Research Director, Pain Research Department of Anesthesiology
More informationFibromyalgia or Arthritis
Fibromyalgia or Arthritis Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More information10/19/12. Moving from Mechanisms to Treatment in Chronic Pain Patients. Daniel Clauw, MD Disclosures
10/19/12 Moving from Mechanisms to Treatment in Chronic Pain Patients Daniel Clauw, MD University of Michigan Ann Arbor, MI Daniel Clauw, MD Disclosures Research/Grants: Forest Laboratories, Inc.; Nuvo
More informationCANADIAN STROKE BEST PRACTICE RECOMMENDATIONS. Stroke Rehabilitation Evidence Tables Rehabilitation to Improve Central Pain
CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS Rehabilitation to Improve Central Pain Hebert, D, Teasell, R (Writing Group Chairs) on Behalf of the STROKE REHABILITATION Writing Group 2015 December 2015
More informationFibromyalgia: Current Concepts Benjamin Wang, M.D., FRCPC Division of Rheumatology Mayo Clinic Jacksonville, FL
Fibromyalgia: Current Concepts 2017 Benjamin Wang, M.D., FRCPC Division of Rheumatology Mayo Clinic Jacksonville, FL Grand Rounds Boca Raton Regional Hospital September 26, 2017 2017 MFMER slide-1 Disclosures
More informationBalanced Treatments for Fibromyalgia
ARTHRITIS & RHEUMATISM Vol. 50, No. 9, September 2004, pp 2725 2729 DOI 10.1002/art.20486 2004, American College of Rheumatology EDITORIAL Balanced Treatments for Fibromyalgia Geoffrey O. Littlejohn It
More informationJournal of Central Nervous System Disease. Duloxetine: A Review of Its Safety and Efficacy in the Management of Fibromyalgia Syndrome
Journal of Central Nervous System Disease Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Duloxetine: A Review of Its Safety and Efficacy in the Management
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 3019-9 Program Step Therapy Medication Lyrica capsules, Lyrica Solution, Lyrica CR tablets* (pregabalin) P&T Approval Date 1/08,
More informationPennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016
Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016 Disclosures: Fibromyalgia Update Wayne Blount, MD Speaker has no disclosures
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event
More informationTherapeutic Advances in Musculoskeletal Disease
483894TAB5310.1177/1759720X13483894Therapeutic Advances in Musculoskeletal DiseasePJ Mease, MV Farmer 2013 Therapeutic Advances in Musculoskeletal Disease Original Research Milnacipran combined with pregabalin
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abuse, child, 255 Activities of daily living, energy conservation in, 385 Acupuncture, 400 401 Adrenergic receptors, in pain generation, 286
More informationSpine University s Guide to Fibromyalgia
Spine University s Guide to Fibromyalgia 2 Introduction The official name for fibromyalgia is fibromyalgia syndrome. Fibro means fiber and myalgia means muscular pain or tenderness. Fibromyalgia has been
More informationIndication Review: Fibromyalgia Date of Review: January 2019 End Date of Literature Search: 10/05/2018
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596
More informationFIBROMYALGIA INGRAM F ANDERSON. Consultant Rheumatologist
FIBROMYALGIA INGRAM F ANDERSON Consultant Rheumatologist Fibromyalgia is a riddle wrapped in a mystery inside an enigma Fibromyalgia not a new Disease. 1904: Gowers coined the term fibrositis to describe
More informationManagement of Pain related to Spinal Cord Lesion
Management of Pain related to Spinal Cord Lesion A Neurologist s Perspective Vincent Mok, MD Associate Professor Division of Neurology Department of Medicine and Therapeutics The Chinese University of
More informationIF I M NOT TREATING WITH OPIOIDS, THEN WHAT AM I SUPPOSED TO USE?
NON-OPIOID TREATMENT OPTIONS FOR CHRONIC PAIN Alison Knutson, PharmD, BCACP Medication Management Pharmacist Park Nicollet Creekside Clinic Dr. Knutson indicated no potential conflict of interest to this
More informationUse of Pregabalin for Postoperative Pain: Outcomes in 2 Trials
Use of Pregabalin for Postoperative Pain: Outcomes in 2 Trials Jacques E. Chelly, 1 Neil Singla, 2 David R. Lionberger, 3 Henrik Kehlet, 4 Luis Sanin, 5 Jonathan Sporn, 5 Ruoyong Yang, 5 Raymond C. Cheung,
More informationFibromyalgia summary. Patient leaflets from the BMJ Group. What is fibromyalgia? What are the symptoms?
Patient leaflets from the BMJ Group Fibromyalgia summary We all get aches and pains from time to time. But if you have long-term widespread pain across your whole body, you may have a condition called
More informationIndication Review: Fibromyalgia Date of Review: January 2019 End Date of Literature Search: 10/05/2018
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596
More informationNew service available for VoY Ryedale practice patients
New service available for VoY Ryedale practice patients Scarborough Pain (Enablement) Service For some time, NHS Scarborough & Ryedale CCG and York Teaching Hospital Foundation Trust have had a service
More informationFIBROMYALGIA: THE ROLE OF ANTIDEPRESSANT AGENTS
Chapter FIBROMYALGIA: THE ROLE OF ANTIDEPRESSANT AGENTS M. D. Schafranski, A. B. Merlini, A. L. O. Prestes, B. Ribeiro, J. G. Silva and M. F. Gauer Faculty of Medicine Universidade Estadual de Ponta Grossa
More informationLYRICA FOR THE TREATMENT OF NEUROPATHIC PAIN DISORDERS
Volume 20, Issue 7 April 2005 LYRICA FOR THE TREATMENT OF NEUROPATHIC PAIN DISORDERS Tanja Lepir, Pharm.D. Candidate Nervous system dysfunction leading to neuropathic pain can occur from many causes: infection,
More informationFor personal use only
For mass reproduction, content licensing and permissions contact Dowden Health Media. Fib Copyright Dowden Health Media For personal use only Repeated pain signals in the periphery may sensitize spinal
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER. Volume: Page:
SYNOPSIS Protocol No: OROS-ANA-3001 Title of Study: Randomized, open-label, comparative parallel group study to assess efficacy and safety of flexible dosages of OROS hydromorphone once-daily compared
More informationPain and fibromyalgia
Jatin D Dedhia DA DNB FRCA Margaret E Bone DA FRCA FFPMRCA Key points Fibromyalgia is a common chronic pain syndrome characterized by widespread pain, tenderness, and generalized hypersensitivity to painful
More informationDrug Use Evaluation: Newer Antiepileptic Drugs Executive Summary
Drug Use Research & Management Program Oregon State University, 3303 SW Bond Av CH12C, Portland, Oregon 97239 4501 Phone 503 494 9954 Fax 503 494 1082 Drug Use Evaluation: Newer Antiepileptic Drugs Executive
More informationCharacteristics and healthcare costs of patients with fibromyalgia syndrome
ORIGINAL PAPER Characteristics and healthcare costs of patients with fibromyalgia syndrome A. Berger, 1 E. Dukes, 2 S. Martin, 2 J. Edelsberg, 1 G. Oster 1 doi: 10.1111/j.1742-1241.2007.01480.x OnlineOpen:
More informationNeuropathic pain MID ESSEX LOCALITY
Neuropathic pain Neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory nervous system. A. Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) i Read questions to
More informationLiterature Scan: Topical Analgesics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationFibromyalgia: What We Have Learned and How Treatment Is Evolving. Education Partner:
Fibromyalgia: What We Have Learned and How Treatment Is Evolving Education Partner: St. Louis, Missouri November 13, 2008 Session 3: Fibromyalgia: What We Have Learned and How Treatment Is Evolving Learning
More informationMANAGEMENT OF DIABETIC NEUROPATHY. Chungnam University Hospital Soo-Kyung, Bok, M.D., Ph.D.
MANAGEMENT OF DIABETIC NEUROPATHY Chungnam University Hospital Soo-Kyung, Bok, M.D., Ph.D. The Diabetic neuropathy cannot be reversed Not to restore function to damaged nerve Slowly progress no initial
More informationAn investigantional clinical evaluation of efficacy of milnacipran compared with sodium oxybate in patients suffering with fibromyalgia
IJPAR Vol.6 Issue 2 April - June -2017 Journal Home page: ISSN:2320-2831 Research article Open Access An investigantional clinical evaluation of efficacy of milnacipran compared with sodium oxybate in
More informationFmonly associated with other symptoms, including physical
Duloxetine Teatment Outcomes in Fibromyalgia Efficacy of Duloxetine in Patients With Fibromyalgia: Pooled Analysis of 4 Placebo-Controlled Clinical Trials Lesley M. Arnold, MD; Daniel J. Clauw, MD; Madelaine
More informationReview. Pharmacological treatment of fibromyalgia
Review Pharmacological treatment of fibromyalgia M. Di Franco 1, C. Iannuccelli 1, F. Atzeni 2, M. Cazzola 3, F. Salaffi 4, G. Valesini¹, P. Sarzi-Puttini 2 1 Chair of Rheumatology, Sapienza, University
More informationSUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP)
9 SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP) SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF ACUTE PAIN NONOPIOID TREATMENTS
More informationFibromyalgia. Anisur Rahman, 1 Martin Underwood, 2 Dawn Carnes 3 CLINICAL REVIEW
Follow the link from the online version of this article to obtain certified continuing medical education credits Fibromyalgia Anisur Rahman, 1 Martin Underwood, 2 Dawn Carnes 3 1 Department of Rheumatology,
More informationIs Laser Therapy an Effective Alternative Treatment for Women With Fibromyalgia?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2016 Is Laser Therapy an Effective Alternative
More informationAuthor: Gibler/Ketchum Date: March 2015
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More information9/6/2011. Objectives THE FIBROMYALGIA SYNDROME: HOW FAR HAVE WE COME IN OUR UNDERSTANDING & MANAGEMENT
THE FIBROMYALGIA SYNDROME: HOW FAR HAVE WE COME IN OUR UNDERSTANDING & MANAGEMENT Theresa Mallick-Searle Nurse Practitioner Stanford University Medical Center: Division Pain Management tmallick@stanfordmed.org
More informationSpecific question: Does acupuncture improve pain, function and quality of life for adults with fibromyalgia?
Specific question: Does acupuncture improve pain, function and quality of life for adults with fibromyalgia? Clinical bottom line There is low to moderate level evidence that western and electro acupuncture
More informationChapter 23 Pharmacological therapies in fibromyalgia (chronic widespread pain)
Breivik_23.qxd 18/09/2006 11:34 Page 239 Chapter 23 Pharmacological therapies in fibromyalgia (chronic widespread pain) Srinivas G. Rao and Robert M. Bennett INTRODUCTION As detailed elsewhere in this
More informationReceived 13 July 2007; received in revised form 14 February 2008; accepted 20 February 2008
Pain 136 (2008) 419 431 www.elsevier.com/locate/pain Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): A 6-month, double-blind, placebo-controlled trial with pregabalin
More information8/6/18. Definitions. Disclosures. Technician Objectives. Pharmacist Objectives. Chronic Pain. Non-Opioid Alternatives for Chronic Pain Management
Disclosures Non-Opioid Alternatives for Chronic Management Nicholas Cox, PharmD, BCACP Clinical Pharmacist, Intensive Outpatient Clinic, University of Utah Health Pharmacist, Population Health, University
More informationNew Evidence reports on presentations given at ACR Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab
New Evidence reports on presentations given at ACR 2009 Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab From ACR 2009: Rituximab Rituximab in combination with methotrexate
More informationThe scenario is familiar: A woman, typically
FIBROMYALGIA: WHAT IT IS AND HOW IT RELATES TO OTHER UNEXPLAINED ILLNESSES* Benjamin H. Natelson, MD ABSTRACT Fibromyalgia (FM), which primarily affects women, is one of several medically unexplained illnesses.
More informationPerceived contributing factors, locus of control and self-efficacy in patients with fibromyalgia syndrome (FMS)
The University of Toledo The University of Toledo Digital Repository Theses and Dissertations 2011 Perceived contributing factors, locus of control and self-efficacy in patients with fibromyalgia syndrome
More informationObjectives. Objectives. Fibromyalgia overview 2/13/2013. Disclosure. FM research has flourished since 1980s. Acceptance fibromyalgia as a diagnosis
Fibromyalgia overview Robert Bennett M.D. Professor of Medicine Mdii and Nursing OHSU Disclosure Research support : Forest, Jazz, Pfizer Advisory Boards: Lilly, Jazz Speaker Bureaus: None Objectives Objectives
More informationMEDICAL POLICY SUBJECT: KETAMINE INFUSION THERAPY FOR THE TREATMENT OF CHRONIC PAIN SYNDROMES POLICY NUMBER: CATEGORY: Technology Assessment
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationGuideline scope Persistent pain: assessment and management
National Institute for Health and Clinical Excellence [document type for example, IFP, QRG] on [topic] Document cover sheet Date Version number Editor 30/08/2017 1 NGC Action 1 2 3 4 5 6 7 8 9 10 11 12
More informationMoving On : Non-Opioid Alternatives for Chronic Pain Management
Winter Meeting February 10, 2018 Moving On : Non-Opioid Alternatives for Chronic Pain Management Nicholas Cox, PharmD, BCACP Clinical Pharmacist, Intensive Outpatient Clinic, University of Utah Health
More informationPregabalin As A Treatment for Generalized Anxiety Disorder. Ashley Storrs PGY III December 2, 2010
Pregabalin As A Treatment for Generalized Anxiety Disorder Ashley Storrs PGY III December 2, 2010 Background Information Approximately 18.1 percent of American adults 18 years or older have an anxiety
More informationChoices Before Opioids
Choices Before Opioids For CNCP Planning committee Academic Content Experts Clinical reviewers Maureen Allen, MD BN CCFP-EM(PC), Associate Professor, Emergency Medicine, St. Martha s Regional Hospital,
More information